Skip to main content
SpringerLink
Log in

Childhood Acute Nonlymphoblastic Leukemia — Results of the Austrian-Hungarian Acute Myeloid Leukemia Studies IGCI-84 and 90

  • Conference paper
Acute Leukemias VI

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 38))

  • 181 Accesses

Abstract

Between 1984 and 1992, 154 children and adolescents were registered to the two consecutive Austrian-Hungarian cooperative multicenter childhood acute nonlymphoblastic leukemia (ANLL), studies AML-IGCI-84 and 90. A total of 148 patients were evaluable for treatment response. Both protocols represented modifications of the German Berlin-Frankfurt-Minster (BFM) study protocols AML-BFM-83 and-87, respectively. Aclarubicin (ACR) was substituted for daunorubicin in the first-line induction protocol. In addition, two courses of high-dose cytosine arabinoside plus idarubicin or mitoxantrone, respectively, were given as early intensification in the IGCI-90 series instead of the late intensification courses of BFM-87. From IGCI-84 (n = 95) to IGCI-90 (n = 53) the remission rate improved from 67% to 77%, and probability of event-free survival (pEFS) from.30 to.37 (not significant, median follow up in complete remission (CR) 8.1 and 3.9 years, respectively). Remission duration was not improved (probability of event-free interval, pEFI,.44 vs..48). A relatively high death rate in CR and the omission of cranial irrradiation in the second study may have been the main reasons for the lack of improvement of results.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Creutzig U, Ritter J, Riehm H, et al. (1985) Improved treatment results in childhood acute myelogenous leukemia, Blood 65: 298–304

    PubMed  CAS  Google Scholar 

  2. Creutzig U, Ritter J, Schellong G (1990) Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 75: 1932–1940

    PubMed  CAS  Google Scholar 

  3. Ritter I, Creutzig U, Schellong G (1992) Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group. Leukemia 6 (Suppl 2): 59–62

    PubMed  Google Scholar 

  4. Buckley JD, Chard RL, Baehner RL, et al. (1989) Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Children’s Cancer Study Group. Cancer 63: 1457–1465

    Article  PubMed  CAS  Google Scholar 

  5. Buckley ID, Lampkin B, Nesbit M, et al. (1989) Remission induction in children with acute nonlymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group. Med Pediatr Oncol 17: 382–390

    Article  PubMed  CAS  Google Scholar 

  6. Nesbit ME, Buckley ID, Feig SA, et al. (1994) Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by bone marrow transplantation or multiagent chemotherapy: a report from the Children’s Cancer Group. I Clin Oncol 12: 127–135

    Google Scholar 

  7. Steuber CP, Civin C, Krischer J, et al. (1991) A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study. I Clin Oncol 9: 247–258

    CAS  Google Scholar 

  8. Weinstein HJ, Mayer RJ, Rosenthal DS, et al. (1983) Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 62: 315–319

    PubMed  CAS  Google Scholar 

  9. Grier HE, Gelber RD, Link MP, et al. (1992) Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze. Leukemia 6 (Suppl 2): 48–51

    PubMed  Google Scholar 

  10. Chessells JM, O’Callaghan U, Hardisty RM (1986) Acute myeloid leukaemia in childhood: clinical features and prognosis. Br J Haematol 63: 555–564

    Article  PubMed  CAS  Google Scholar 

  11. Oki T, Matsuzawa Y, Yoshimoto A, et al. (1975) New antitumor antibiotics, aclacinomycin A and B. J Antibiot (Tokyo) 28: 830–834

    CAS  Google Scholar 

  12. Yamada K, Nakamura T, Tsurno T, et al. (1980) A phase II study of aclacinomycin A in acute leukemia in adults. Cancer Treat Rev 7: 177–182

    Article  PubMed  CAS  Google Scholar 

  13. Warrell RP, Arlin ZA, Zempin SJ, Young CW (1982) Phase I-II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia. Cancer Treat Rep 66: 1619–1623

    PubMed  Google Scholar 

  14. Pedersen-Bjergaard J, Brincker H, Ellegard J, et al. (1984) Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial. Cancer Treat Rep 68: 1233–1238

    PubMed  CAS  Google Scholar 

  15. Machover D, Gastiaburu J, Delgado M, et al. (1984) Phase I-II study of aclarubicin for treatment of acute myeloid leukemia. Cancer Treat Rep 68: 881–886

    PubMed  CAS  Google Scholar 

  16. Mitrou PS, Kuse R, Angers H, et al. (1985) Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukemias. Eur J Cancer Clin Oncol 21:919–923

    Article  PubMed  CAS  Google Scholar 

  17. Dabich L, Bull FA, Beltran G, et al. (1986) Phase II evaluation of aclarubicin in refractory adult acuteleukemia: a Southwest Oncology Group study. Cancer Treat Rep 70: 967–969

    PubMed  CAS  Google Scholar 

  18. Case DC, Ervin TJ, Boyd MA, et al. (1987) Phase II study of aclarubicin in acute myeloblastic leukemia. Am J Clin Oncol 10: 523–526

    Article  PubMed  Google Scholar 

  19. Dantchev D, Slioussarchouk V, Paintrand M, et al. (1979) Electron microsopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detrubicin, AD-32, and aclacinomycin. Cancer Treat Rep 63: 875–888

    PubMed  CAS  Google Scholar 

  20. Wakabayashi T, Oki T, Tone H, et al. (1980) A comparative electron microscopic study of aclacinomycin and adriamycin cardiotoxicities in rabbits and hamster. J Electron Microsc 29: 106–118

    CAS  Google Scholar 

  21. Warrell RP Jr. (1986) Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the hematologic cancers. Drugs Exptl Clin Res 12: 275–282

    Google Scholar 

  22. Bennett JM, Catovsky D, Daniel MT, et al. (1976) Proposals for the classification of the acute leukemias. French-American-British (FAB) cooperative groups. Br J Haematol 33: 451–458

    Article  PubMed  CAS  Google Scholar 

  23. Bennett JM, Catovski D, Daniel MT, et al. (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report from the French-American-British cooperative group. Ann Intern Med 103: 620–627

    PubMed  CAS  Google Scholar 

  24. Bennett JM, Catovsky D, Daniel MT, et al. (1985) Criteria for the diagnosis of acute leukemia of megakaryocytic lineage (M7). A report of the French-American-British cooperative group. Ann Intern Med 103: 460–462

    PubMed  CAS  Google Scholar 

  25. Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481

    Article  Google Scholar 

  26. Peto R, Pike M C (1973) Conservatism of the approximation Σ(O – E)2/E in the logrank test for survival data or tumor incidence data. Biometrics 29:579–584

    Article  PubMed  CAS  Google Scholar 

  27. Linkesch W, Thaler J, Gattringer C, Konwalinka G. Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds.): Haematology and blood transfusion 33, Acute leukemias II, pp 330–332, Springer, Berlin, Heidelberg, 1990

    Google Scholar 

  28. Rowe JM, ChangAY, Bennett JM (1988) Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood 71: 992–996

    PubMed  CAS  Google Scholar 

  29. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, et al. (1991) Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. Leukemia 5: 510–516

    PubMed  CAS  Google Scholar 

  30. Creutzig U, Ritter J, Zimmermann M, Schellong G (1993) Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol 11: 279–86

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Innsbruck, Austria

    F. M. Fink

  2. St. Anna Children’s Hospital, CCRI, Vienna, Austria

    G. Mann, E. R. Panzer-Grümayer & H. Gadner

  3. Teaching Hospital Szombathely, Hungary

    P. Masát

  4. Semmelweis University Medical School, Budapest, Hungary

    D. Schuler

  5. Department of Pediatric Hematology/Oncology, University of Graz, Austria

    C. Urban

Authors
  1. F. M. Fink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Masát
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. R. Panzer-Grümayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Kajtar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Kardos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Urban
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Gadner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Münster, Albert-Schweitzer-Strasse 33, 48145, Münster, Germany

    T. Büchner

  2. Department of Pediatrics, University of Münster, Albert-Schweitzer-Strasse 33, 48145, Münster, Germany

    G. Schellong , J. Ritter  & U. Creutzig ,  & 

  3. Department of Internal Medicine, University of Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Germany

    W. Hiddemann  & B. Wörmann  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Fink, F.M. et al. (1997). Childhood Acute Nonlymphoblastic Leukemia — Results of the Austrian-Hungarian Acute Myeloid Leukemia Studies IGCI-84 and 90. In: Büchner, T., Schellong, G., Ritter, J., Creutzig, U., Hiddemann, W., Wörmann, B. (eds) Acute Leukemias VI. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 38. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60377-8_112

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60377-8_112

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64379-8

  • Online ISBN: 978-3-642-60377-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation